The newly listed clinical-stage biotechnology company, Metsera Inc. rose 15.01% on Monday as the broader markets declined.

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...

Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...

Cantor Fitzgerald initiated coverage on shares of Metsera (NASDAQ:MTSR – Free Report) in a report issued on Tuesday,Benzinga reports. The brokerage issued an overweight rating on the stock.

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) (“Metsera” or the “Company”), a clinical-stage biopharmaceutical company accelerating ...

Check Out Our Latest Analysis on MTSR Metsera Stock Performance NASDAQ:MTSR opened at $24.78 on Thursday. Metsera has a 1-year low of $24.19 and a 1-year high of $32.81. About Metsera (Get Free ...

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to ...

Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. The company is ready to scale up ...